Compare Heron Therapeutics Inc (HRTX) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Merck & Co., Inc. — how do they compare? Heron Therapeutics Inc trades at $0.36 (market cap $68.01M), while Merck & Co., Inc. trades at $141.96 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 5165.1× Heron Therapeutics Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Merck & Co., Inc. for 98 Days on average.
| HRTX | MRK | |
|---|---|---|
Market Cap | $68.01M | $351.28B |
Volume | 1,891,941 | 7,969,665 |
Sector | Health | Health |
52-Week High | $1.49 | $156.43 |
52-Week Low | $0.27 | $82.49 |
Typical Hold Time | 35 Days | 98 Days |
Enterprise Value | $174.75M | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
